Lab tests – Pricing comparison

Lab Test Pricing comparison ( Metropolis / 1Mg/ PharmEasy)

600 Pricing strategies Pharmeasy can adopt –
500
400  Competitive Pricing:Continue offering
300 competitive prices for individual lab
200
tests, especially for popular ones like
100
"Vitamin D 25" and "Thyroid Profile.“
0
Vitamin Vitamin Lipid Thyroid Liver Kidney CBC
D 25 B12 Profile Profile Function Function
 Membership Programs: Introduce a
membership program where customers
1 MG PharmEasy
pay a monthly or annual fee to access
exclusive discounts on lab tests.
Average discount on tests (TATA 1 Mg V/S PharmEasy)
 Corporate Partnership: Provide bulk
78%73%
testing services with corporate discounts,
57%
50%
44%
50% 51% 50% promoting health and wellness in the
43% 43% 41%
35% 36%
25%
workplace.

Vitamin Vitamin Lipid Thyroid Liver Kidney CBC

D 25 B12 Profile Profile Function Function

Average Discount (1 Mg) Average Discount (PharmEasy)

SWOT Analysis – Comparison (PharmEasy V/S 1Mg)
PharmEasy Tata 1Mg
• Less costly
• Diverse Product Portfolio
• Ease of Payments
• Technological Integration
Strength • Convenient and User-friendly
• Supply Chain Integration
• Upgraded Technology
• Brand Recognition (TATA Group)
• Increase use of Mobile Health Solutions

• Non-trained Pharmacist • Dependency on Third-Party Sellers

Weakness • Unsafe Delivery of Medicines • Limited Physical Presence
• The Belief of fake and low-quality medicines • High Customer Acquisition Cost

• Internet Coverage in rural areas • Health Tech Innovations

• Increase in market value • Strategic Partnerships
Opportunity
• Demand for Healthcare Services • Telehealth Market Growth
• Medical requirements at single platform • Focus on Preventive Healthcare

• Political Instability • Regulatory Changes

• Unstructured Grievance Handling System • Supply Chain Disruptions
Threads
• Increasing Competition Between Online & • Market Saturation
Offline • Changing Consumer Behaviour
Gross Merchandise Value (GMV) in Fiscal 2022, 2023
Rs. In Million

Gross Merchandise Value As of and For Fiscal 2022 As of and For Fiscal 2023

Distribution to Retailers 21,143.60 17,039.53

Distribution to Chemist / 31,893.41 36,610.17

Institution (Retailio 1P)

Distribution to Hospitals 31,893.41 13,264.19

(Aknamed)

Retailio 3P 31,893.41 70,681.14

Thyrocare 5,795.35 4,632.02
API diagnostics 773.83 1,236.08
Total 1,34,576.43 1,43,463.14
 Net Revenue for Fiscal 2022, Fiscal 2023 (Consolidated)
Rs. In Million

Revenue As of and For Fiscal 2022 As of and For Fiscal 2023

Sale of Products (A) 52,282.28 59,839.34

Distribution to Retailer 18,834.76 15,194.34

Distribution to Chemist / 18,834.76 32,646.08

Institution (Retailio 1P)
Distribution to Hospitals
(Aknamed) 18,834.76 11,996.92

Sale of Services (B) 5,005.93 7,211.85

Thyrocare 2,920.86 4,632.02
API diagnostics 773.83 1,236.08
Other services 1,311.24 1,343.75
Total (A + B) 57,288.21 67,051.19
5